BiondVax Signs Expanded Agreement with Max Planck Society to Develop Nanosized Antibody Therapies
BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a Jerusalem based biopharmaceutical company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, has signed…
Continue Reading
BiondVax Signs Expanded Agreement with Max Planck Society to Develop Nanosized Antibody Therapies